SeaSpine Holdings Corporation announced preliminary financial results for the fourth quarter and full year of 2019, with U.S Spinal Implants revenues expected to reflect growth within the 20% to 21% range. Preliminary and unaudited revenue for fourth quarter 2019 is expected to be in the range of $43.4 to $43.8 million, reflecting approximately 14% to 15% growth compared to the prior year period. Fourth quarter 2019 U.S. revenue is expected to be in the range of $39.1 to $39.4 million, reflecting 15% to 16% growth compared to the fourth quarter 2018, with U.S. Orthobiologics revenues expected to reflect growth within the 10% - 11% range for the fourth quarter. International revenue is expected to increase more than 8% to approximately $4.3 to $4.4 million. Preliminary and unaudited full-year 2019 revenue is expected to be in the range of $158.7 to $159.1 million, reflecting growth of approximately 11% over full-year 2018. The company expects full-year 2020 revenue to be in the range of $177 to $181 million, reflecting growth of approximately 12% to 14% over full-year 2019. Growth in the U.S. Spinal Implants portfolio for the full-year 2020 is expected to exceed 15%.